Selenium pretreatment enhances the radioprotective effect and reduces the lethal toxicity of WR-2721.
Although WR-2721, S-2-(3-aminopropylamino)ethylphosphorothioic acid, is an effective radioprotector, its use is limited by its toxicity. Combining WR-2721 with other agents might decrease its toxicity and/or increase its effectiveness. The effect of selenium (Se) pretreatment on the acute toxicity and radioprotective effect of WR-2721 was studied in male CD2F1 mice. Injection of 1.6 mg/kg Se 24 hr before WR-2721 (800-1200 mg/kg, IP) decreased the lethality of WR-2721 significantly. Lower doses of Se were also effective, but simultaneous administration was not effective. Se injection alone (1.6 mg/kg) 24 hr before cobalt-60 irradiation increased the survival (dose reduction factor, DRF = 1.1) significantly. A synergistic effect on post-irradiation survival was observed when Se was injected 24 hr before WR-2721 (200-600 mg/kg IP 1/2 before irradiation). For example, after exposure to 22 Gy (1 Gy/min), 30-day survival was 100% when mice were treated with both Se and 600 mg/kg WR-2721, and was 13% with WR-2721 alone. The DRF after 400 mg/kg WR-2721 was 2.6 with Se compared to 2.2 without Se pretreatment. Alkaline phosphatase activity in bone marrow cells and serum was significantly depressed after treatment with 1.6 mg/kg Se, suggesting that a retardation of conversion of WR-2721 to its active free sulfhydryl form through the action of alkaline phosphatase might be partly responsible for the effects of Se. Other possible mechanisms related to the antioxidant properties of Se are under investigation.
Weiss
J F
JF
Radiation Biochemistry Department, Armed Forces Radiobiology Research Institute, Bethesda, Maryland 20814-5145.
Hoover
R L
RL
Kumar
K S
KS
D000469:Alkaline Phosphatase / Q000378:metabolism; D004999:Amifostine / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D001853:Bone Marrow / Q000187:drug effects / Q000201:enzymology / Q000528:radiation effects; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009946:Organothiophosphorus Compounds / Q000494:pharmacology*; D011837:Radiation-Protective Agents / Q000633:toxicity; D012643:Selenium / Q000627:therapeutic use*
D009946:Organothiophosphorus Compounds; D011837:Radiation-Protective Agents; D000469:Alkaline Phosphatase; D012643:Selenium; D004999:Amifostine